Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab +/- Docetaxel in HRPC
NCT00050596Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2002
- Primary completion
- Nov 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab in prostate cancer (PCa) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and Adverse Events and Prostate Specific Antigen Response. Started Nov 2002; status: completed.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00050596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050596.